Evidence map›Paper›PMID 24013129›Full record

ArticleJournal of proteomics2013

Isolation and analysis of linker histones across cellular compartments.

Sean W Harshman, Michael M Chen, Owen E Branson, Naduparambil K Jacob, Amy J Johnson, John C Byrd, Michael A Freitas

Abstract read
In one paragraph

Article in Journal of proteomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Epigenetics and autism spectrum disorder: A report of an autism case with mutation in H1 linker histone HIST1H1E and literature review.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2018
    Review
  5. Article
  6. Histone H1 phosphorylation in breast cancer.Journal of proteome research · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sean W HarshmanDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Michael M Chen
Owen E Branson
Naduparambil K Jacob
Amy J Johnson
John C Byrd
Michael A Freitas
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
Assays for Screening Histone Modifications in CancerR01CA107106 · NCI · OHIO STATE UNIVERSITY · PI FREITAS, MICHAEL A. · 2004 to 2013
$1.8M
Assays for Screening Histone Modificaitons in CancerR56CA107106 · NCI · OHIO STATE UNIVERSITY · PI FREITAS, MICHAEL A. · 2009 to 2009
$231k
NCI NIH HHS P01 CA081534NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA107106NCI NIH HHS R56 CA107106
6 · The paper itself

Abstract

Analysis of histones, especially histone H1, is severely limited by immunological reagent availability. This paper describes the application of cellular fractionation with LC-MS for profiling histones in the cytosol and upon chromatin. First, we show that linker histones enriched by cellular fractionation gives less nuclear contamination and higher histone content than when prepared by nuclei isolation. Second, we profiled the soluble linker histones throughout the cell cycle revealing phosphorylation increases as cells reach mitosis. Finally, we monitored histone H1.2-H1.5 translocation to the cytosol in response to the CDK inhibitor flavopiridol in primary CLL cells treated ex vivo. Data shows that all H1 variants translocate in response to drug treatment with no specific order to their cytosolic appearance. The results illustrate the utility of cellular fractionation in conjunction with LC-MS for the analysis of histone H1 throughout the cell. BIOLOGICAL SIGNIFICANCE: This paper demonstrates the first time application of cellular fractionation to characterize cytosolic histone H1 by liquid chromatography mass spectrometry (LC-MS). Using the Ramos Burkitt's lymphoma cell line, cellular fractionation was shown to give less nuclear contamination and higher histone content than preparations by nuclei isolation. Further application of the cellular fractionation approach was shown by using primary chronic lymphocytic leukemia (CLL) cells to monitor the movement of histone H1 across cellular compartments in response to the cyclin dependent kinase inhibitor flavopiridol. Collectively, these data establish a mass spectrometric method for exploration into the function of cytosolic histone H1.

Indexed as

Gene Expression Regulation, LeukemicCell Line, TumorCell NucleusChromatinChromatography, LiquidCytosolGene Expression ProfilingHistonesHumansLeukemia, Lymphocytic, Chronic, B-CellMass SpectrometryMitosisPhosphorylationSubcellular FractionsChromatinHistonesCellular compartmentalizationHistone H1LC–MS

Identifiers

PMID24013129
PMCPMC3863389
OpenAlexW2088741140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.